These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16166766)

  • 1. Future directions in multiple myeloma treatment.
    Child JA; Russell N; Sonneveld P; Schey S
    Acta Haematol; 2005; 114 Suppl 1():8-13. PubMed ID: 16166766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future role of thalidomide in multiple myeloma.
    Boccadoro M; Blade J; Attal M; Palumbo A
    Acta Haematol; 2005; 114 Suppl 1():18-22. PubMed ID: 16166768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
    Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL
    Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for relapsed and refractory multiple myeloma.
    Lonial S; Mitsiades CS; Richardson PG
    Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide: a new therapy for multiple myeloma.
    Palumbo A; Miguel JS; Sonneveld P; Moreau P; Drach J; Morgan G; Einsele H
    Cancer Treat Rev; 2008 May; 34(3):283-91. PubMed ID: 18230411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
    Ahn JS; Yang DH; Jung SH; Park HC; Moon JH; Sohn SK; Bae SY; Kim YK; Kim HJ; Lee JJ;
    Ann Hematol; 2012 Jul; 91(7):1023-30. PubMed ID: 22314843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
    Steurer M; Spizzo G; Mitterer M; Gastl G
    Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide: an update on evidence from clinical trials.
    Dimopoulos MA; Terpos E
    Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
    Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
    Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in multiple myeloma: current role and future directions.
    Zeldis JB; Knight RD; Jacques C; Tozer A; Bizzari JP
    Expert Opin Pharmacother; 2010 Apr; 11(5):829-42. PubMed ID: 20210686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
    Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of thalidomide in multiple myeloma.
    Schwab C; Jagannath S
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.
    García-Sanz R; González-Porras JR; Hernández JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; López R; Grande-García C; Alegre A; Vargas-Pabón M; Gutiérrez ON; Rodríguez JA; San Miguel JF
    Leukemia; 2004 Apr; 18(4):856-63. PubMed ID: 14973508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.